DENTAL BOTOKS UYGULAMALARI

Year 2019, Volume: 1 Issue: 3, 89 - 102, 31.10.2019

Deniz Erdil Hamed Farsiani Nilsun Bağış

Abstract

    Botulinum toksini (BT) Clostridium Botulinum
tarafından anaerobik koşullar altında üretilen en ölümcül toksinlerden biridir.
BT, kolinerjik nöron sinapslarında asetilkolin salınımını bloke ettiği
nöromüsküler kavşak (NMJ) üzerindeki etkisiyle kas felcine neden olduğunun
öğrenilmesinden itibaren tıpta ve kozmetik alanda kullanılmaya başlanmıştır.
Dünyada en yaygın olarak kullanılan BTA Botox®faciodental estetik ve terapötik
amaçlara yönelik olarak diş hekimliğinde de kendine yer bulmuştur.  BT’nın terapötik ve dentofasiyal estetik
kullanımda etkili ve güvenli sonuçlar elde edilmiştir. Özellikle temporo
mandibuler bozukluklar, bruksizm, gummy smile gibi vakalarda radikal cerrahiye
göre çok daha az invaziv olması ve yardımcı tedavi olarak fayda sağlaması nedeniyle
kendine yer edinmiştir. BT'nın terapötik etkisi geçici ve nispeten güvenli
olmasına rağmen, ilgili anatomi ve yüze uygulanan ilaçların sistemik ve lokal
yan etkileri hakkında bilgi sahibi olmak esastır.

Keywords

Botulinum toksin A, bruksizm, diş hekimliği

APPLICATION OF DENTAL BOTOX

Abstract

    Botulinum
is one of the most lethal toxins known and botulinum neurotoxin produced under
anaerobic conditions by Clostridium Botulinum. BT has been used in medicine and
cosmetics since it has been learned that it causes muscle paralysis due to its
effect on the neuromuscular junction (NMJ) where it blocks acetylcholine release in
cholinergic neuron synapses. The most widely used BTA Botox® in the world has
found its place in dentistry for aesthetic and therapeutic purposes such as
temporomandibular disorders, bruxism, trigeminal neuralgia, oromandibular
spasm, gummy smile, masseterhipertrofisi, sialorrhea. BTA injections are a much
more minimally invasive method than radical surgical procedures and can be used
as an adjunctive treatment. Although the therapeutic effect of CT is transient
and relatively reliable, it is essential to have knowledge of the relevant
anatomy and systemic and local side effects of the drugs administered to the
face.

Keywords

Botulinum toxin A, bruxism, dentistry

References

• 1.Kerner J. Vergiftung durchver dorbene Würste.Tübinger Blätter Naturwissenschaften Arzneykunde1817;3:25.
• 2.Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001;285:1059-70.
• 3.Park KS, Lee CH, Lee JW. JDentAnesthPainMed. 2016 Sep;16(3):151-157.
• 4. Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol 1949; 109: 10-24.
• 5. Erbguth FJ. From poison tor emedy: The chequered history of botulinum toxin. J NeuralTransm (Vienna). 2008; 115: 559-65.
• 6. Scott A. Botulinum toxin injection to correct strabism. Trans Am Ophthalmol Soc. 1979; 79: 924-7.
• 7. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc.1981; 79: 734-70.
• 8. Dastoor SF, Misch CE, Wang HL. Botulinum toxin (Botox) to enhance facial macroesthetics: A literatür ereview. J Oral Implantol. 2007;33(3):164-71.
• 9. Nayyar P., Kumar P., Nayyar PV. Botox: Broadening theHorizon of Dentistry.J ClinDiagnRes. 2014 Dec;8(12):ZE25-9.
• 10. Srivastava S, Kharbanda S, Pal US, Shah V. Applications of botulinum toxin in dentistry: A comprehensive review.Natl J MaxillofacSurg. 2015 Jul-Dec;6(2):152-9.
• 11. Kao I, Drachman DB, Price DL. Botulinum toxin: Mechanism of presynapticblockade. Science. 1976; 193: 1256-8.
• 12. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. PharmacolRev. 1981; 33: 155-88.
• 13. Jaspers GW, Pijpe J, Jansma J. The use of botulinum toxin type a in cosmetic facial procedures. Int J Oral MaxillofacSurg. 2011; 40: 127-33.
• 14. de Maio M. Therapeutic uses of botulinum toxin: From facial palsy to autonomic disorders. Expert OpinBiolTher 2008; 8: 791-8.
• 15. Lora VR, CanalesGde L, Goncalves LM, Meloto CB, Barbosa CM. Prevalence of temporomandibular disorders in post menopausal women and relationship with pain and HRT. Braz Oral Res. 2016.30(1): e100.
• 16.Schwartz M, Freund B. Botulinum Toxin a Therapy for Temporomandibular Disorders. Philadelphia, Pa: Lippincott Williams &Wilkins, 2002.
• 17.Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain. 2002;18(6 Suppl):S198-203.
• 18. Castenada R. Occlusion. In: Kaplan A, Assael L (eds). Temporomandibular Disorders. Philadelphia, Pa: Saunders, 1992.
• 19.Freund B, Schwartz M, Symington JM. Theuse of botulinum toxin for the treatment of temporomandibular disorders: Preliminary findings. J Oral MaxillofacSurg.1999;57:916-20.
• 20.Lee KM, Chow J, Hui E, Li W. Botulinum toxin type A injection for the management of myofascial temporomandibular pain disorder. Asian J Oral MaxillofacSurg. 2005;17:100-3
• 21.Moore AP, Wood GD. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin A. BrDent J. 1997; 183:415-7.
• 22. Daelen B, Thorwirth V, Koch A. Treatment of recurrent dislocation of the temporomandibular joint with type A botulinum toxin. Int J Oral MaxillofacSurg. 1997; 26:458-60.
• 23.Fu KY, Chen HM, Sun ZP, Zhang ZK, Ma XC. Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint. Br J Oral MaxillofacSurg. 2010; 48:281-4.
• 24.Freund B, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorders: Preliminary findings. J Oral MaxillofacSurg. 1999; 57: 916-20.
• 25.Bakke M, Moller E, Werdelin LM, Dalager T, Kitai N, Kreiborg S. Treatment of severe temporomandibular joint clicking with botulinum toxin in the lateral pterygoid muscle in two cases of anterior disc displacement. Oral Surg Oral Med Oral Pathol Oral RadiolEndod. 2005; 100: 693-700.
• 26. Daelen B, Thorwirth V, Koch A. Treatment of recurrent dislocation of the temporomandibular joint with type a botulinum toxin. Int J Oral MaxillofacSurg. 1997; 26: 458-60.
• 27. Blitzer A, Brin MF, Greene PE, et al. Botulinum toxin injection for the treatment of oromandibulardystonia. AnnOtolRhinolLaryngol. 1989;98(2):93-97.
• 28.Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemi facial spasm. MovDisord. 1987;2(4): 237-54. 29.Hermanowicz N, Truong DD. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope. 1991;101(11):1216-18.
• 30.Jankovic J, Orman J. Botulinum toxin for cranial-cervicaldystonia: a double-blind, placebo-controlledstudy. Neurology. 1987; 27:616-23.
• 31.Laskawi R, Rohrbach S. Oromandibulardystonia. Clinicalforms, diagnosis and examples of therapy with botulinum toxin. Laryngorhinootologie. 2001;80(12):708-13.
• 32.Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: Long-termfollow-up. Neurology. 1999;53(9):2102-07.
• 33.Sinha A, Hurakadli M, Yadav P. Botox and dermafillers: The twinface of cosmetic dentistry. Int J ContempDentMedRev. 2015;2015.
• 34.Elcio JP. BOTOX injections relieve severe facial pain. Available from: http://www. news-medical.net/news/2005/10/25/14010.aspx. [lastcitedon 2009].
• 35.Bohluli B, Motamedi MH, Bagheri SC, Bayat M, Lassemi E, Navi F, et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: Preliminary report. Oral Surg Oral Med Oral Pathol Oral RadiolEndod.2011;111:47-50
• 36.Benoliel R, Kahn J, Eliav E. 2012. Peripheral painful traumatic trigeminal neuropathies. Oral Dis. 18(4):317–332.
• 37. Rafael B, Sorin T, Eli E. 2016. Painful traumatic trigeminal neuropathy. Oral MaxillofacSurgClin North Am. 28(3):371–380.
• 38. Lobbezoo F, Ahlberg J, Raphael KG, Wetselaar P, Glaros AG, Kato T, Santiago V, Winocur E, De Laat A, De Leeuw R, et al. 2018. International consensus on the assessment of bruxism: report of a work in progress. J Oral Rehabil. 45(11):837–844.
• 39. Manfredini D, Ahlberg J, Winocur E, Lobbezoo F. 2015. Management of sleep bruxism in adults: a qualitative systematic literature review. J Oral Rehabil. 42(11):862–874.
• 40. Jokubauskas L, Baltrušaitytė A, Pileičikienė G. 2017. Oral appliances for managing sleep bruxism in adults: a systematic review from 2007 to 2017. J Oral Rehabil. 45(1):81–95.
• 41. Guarda-Nardini L, Manfredini D, Salmaso S, Salmaso L, Tonello S, Ferronato G. 2008. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 26(2):126–135.
• 42. Lee SJ, McCall WD, Kim YK, Chung SC, Chung JW. 2010. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J PhysMedRehabil. 89(1):16–23.
• 43. Redaelli A. 2011. Botulinum toxin A in bruxers: one year experience. SaudiMed J. 32(2):156–158.
• 44. Shim Y, Lee M, Kato T, Park H, Heo K, Kim S. 2014. Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: a polysomnographic evaluation. J ClinSleepMed. 10(3):291–298.
• 45. Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J. 2018. On a botulinumtoxin-A injections for sleep bruxism. Neurology. 90(7):e559–e564.46.Muñoz Lora VRM, Del Bel Cury AA, Jabbari B, Lacković Z. J DentRes. 2019 Sep 18:22034519875053.
• 47.Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J NeurolNeurosurgPsychiatry. 1990;53(6):530.
• 48. Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J AmDentAssoc. 2000;131(2):211-6.
• 49.Long H, Liao Z, Wang Y, Liao L, Lai W. Efficacy of botulinum toxins on bruxism: An evidence-based review. IntDent J. 2012; 62:1-5
• 50.Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral MaxillofacSurg. 2003; 61:454-7.
• 51.Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: A management challenge. AmFamPhysician. 2004; 69:2628-34.
• 52. Setler PE. Therapeutic use of botulinum toxins: Background and history. Clin J Pain. 2002;18 6 Suppl:S119-24.
• 53. Lim YC, Choi EC. Treatment of an acute salivary fistula after parotid surgery: botulinum toxintype A injection as primary treatment. EurArchOtorhinolaryngol. 2008;265(2):243-45.
• 54.Bentsianov BL, Francis A, Blitzer A. Botulinum toxin treatment of temporomandibular disorders, masseteric hypertrophy, and cosmetic masseter reduction. Operative Techniques in Otolaryngology-Head and NeckSurgery. 2004;15(2):110-13.
• 55.Olivo S, Bravo J, Magee DJ, et al. The association between head and cervical posture and temporomandibular disorders: A systematic review. J OrofacPain. 2006;20(1):9-23.
• 56.Freund B, Schwartz M, Symington JM. Botulinum toxin: New treatment for temporomandibular disorders. Br J Oral MaxillofacSurg .2000;38(5):466-71.
• 57.Freund B, Schwartz M, Symington JM, et al. Theuse of botulinum toxin for the treatment of temporomandibular disorders: Preliminary findings. J Oral MaxillofacSurg. 1999;57(8):916-21.
• 58.Nishimura K, Itoh T, Takaki K, et al. Periodontal parameters of osseo integrated dental implants: A four-year controlled follow-up study. Clin Oral ImplantsRes. 1997;8(4):272-78.
• 59.Kayikcioglu A, Erk Y, Mavif E, et al. Botulinum toxin in the treatment of zygomatic fractures. PlastReconstrSurg. 2003;111(1):341-46.
• 60.Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia:Long-term management with botulinum toxin. Laryngoscope. 2013; 123: 3078-83.
• 61. Armstrong MW, Mountain RE, Murray JA. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type a following facial nerve palsy. ClinOtolaryngolAlliedSci.1996; 21: 15-20.
• 62. Freund BJ, Schwartz M. Intramuscular injection of botulinum toxin as an adjunct to arthrocentesis of the Temporomandibular joint: Preliminary observations. Br J Oral MaxillofacSurg. 2003; 41: 351-2.
• 63. Majid OW. Clinical use of botulinum toxins in oral and maxillofacial surgery. Int J Oral MaxillofacSurg. 2010; 39: 197-207.
• 64. Montoya FJ, Riddell CE, Caesar R, Hague S. Treatment of gustatory hyperl acrimation (crocodiletears) with injection of botulinum toxin into the lacrimal gland. Eye (Lond). 2002;16:705-9
• 65. Bagis N, Barbaros R, Yıldız H. Application of botulinum toxin injection in symmetric and asymmetric gummy smile cases. International Journal of Experimental Dental Science. 2018;7(1):39-42.
• 66.Hwang WS, Hur MS, Hu KS, Song WC, Koh KS, Baik HS, et al. Surface anatomy of the lip elevator muscles for the treatment of gummy smile using botulinum toxin. AngleOrthod. 2009; 79:70-7. 27.
• 67.Polo M. Botulinum toxin type A (Botox) for the neuromuscular correction of excessiv egingival display on smiling (gummysmile). Am J OrthodDentofacialOrthop. 2008;133:195-203.
• 68. Miskinyar SA. A new method for correcting a gummy smile. PlastReconstrSurg.1983;72:397-400
• 69.Polo M. Botulinum toxin type A in thetreatment of excessive gingival display. Am J Orthod Dentofacial Orthop. 2005;127(2):214-18.
• 70.Niamtu J 3rd. Botulinum toxin A: A review of 1,085 oral and maxillofacial patient treatments. J Oral MaxillofacSurg. 2003;61:317-24
• 71.Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxintype A. Br J Oral MaxillofacSurg. 1994;32:26-8.
• 72. Isaac AM. Unilateral temporalis muscle hypertrophy managed with botulinum toxin type A. Br J Oral MaxillofacSurg. 2000; 38:571-2.
• 73.Bentsianov B, Francis A, Blitzer A. Botulinum toxin treatment of temporomandibular disorders, masseteric hypertrophy, and cosmetic masseter reduction. Oper Tech Otolaryngol Head Neck Surg. 2004;15:110-3.
• 74.Ihde SK, Konstantinovic VS. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: An evidence-based review. Oral Surg Oral Med Oral Pathol Oral RadiolEndod. 2007; 104: e1-11
• 75.Clark GT. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. PhysMedRehabilClin North Am. 2003;14(4):727-48.
• 76.Al-Ahmad HT, Al-Qudah MA. The treatment of masseter hypertrophy with botulinum toxin type A. SaudiMed J. 2006;27(3):397-400.
• 77.Mandel L, Tharakan M. Treatment of unilateral masseteric hypertrophy with botulinum toxin: Case report. J Oral MaxillofacSurg. 1999;57(8):1017-19.
• 78.Rijsdijk BA, Van Es RJJ, Zonneveld FW, et al. Botulinum toxin type A treatment of cosmetically disturbing masseteric hypertrophy. NedTijdschrGeneeskd. 1998;142(10):529-32.
• 79.Rao LB, Sangur R, Pradeep S. Application of Botulinum toxin Type A: An arsenal in dentistry. Indian J DentRes. 2011; 22:440-45.
• 80.Choi YJ, Kim JS, Gil YC, Phetudom T, Kim HJ, Tansatit T, et al. Anatomical considerations regarding the location and boundary of the depressor anguli oris muscle with reference to botulinum toxin injection. PlastReconstrSurg. 2014;134:917-21.
• 81.Mazzuco R, Hexsel D. Gummy smile and botulinum toxin: A new approach based on the gingival exposure area. J AmAcadDermatol. 2010; 63:1042-51.
• 82.Azam A, Manchanda S, Thotapalli S, Kotha SB.Botox Therapy in Dentistry: A Review.J Int Oral Health. 2015;7(Suppl 2):103-5.
• 83.Naumann M, Jankovic J. Safety of botulinum toxin type A: A systematic review and meta-analysis. CurrMedResOpin. 2004;20:981-90.
• 84.US FoodandDrug Administration. Information for health care professionals: Onabotulinum toxinA (marketed as Botox/BotoxCosmetic), Abobotulinum toxinA (marketed as Dysport) and Rima botulinum toxinB (marketed as Myobloc). FDA Alert. Rockville, MD: FDA. 2009 Aug.
• 85. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2003; 49:34-8